Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cancer Immunotherapy Market: Current Analysis and Forecast 2021-2027

This image opens in the lightbox

News provided by

UnivDatos Market Insights

26 Apr, 2021, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

- Increasing Cancer Incidence Driving the Cancer Immunotherapy Market with Key Players like AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Janssen Biotech, Merck, and Novartis

NOIDA, India, April 26, 2021 /PRNewswire/ -- A comprehensive overview of the Cancer Immunotherapy market is recently added by UnivDatos Market Insights to its humongous database. The Cancer Immunotherapy Market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. This innovative report makes use of several analyses to get a closer outlook on the Cancer Immunotherapy market. The Cancer Immunotherapy market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Cancer Immunotherapy market at the global and regional level. The Global Cancer Immunotherapy Market is expected to grow at a CAGR of 10.25% from 2021-2027 to reach USD 174.33 billion by 2027.

Market Overview

Global Cancer Immunotherapy Market is experiencing significant growth owing to increasing patient pool and higher mortality rate worldwide. In 2020, there were an anticipated 19.3 million new cancer cases (18.1 million excluding NMSC, except basal cell carcinoma) and 10 million cancer mortality cases (9.9 million excluding NMSC, except basal cell carcinoma) worldwide. Europe accounted for 22.8% of the total cancer cases and 19.6% of the cancer deaths, although it represents 9.7% of the worldwide population, followed by the Americas' 20.9% of incidence and 14.2% mortality globally. However, the cancer deaths share in Asia (58.3%) and Africa (7.2%) were observed to be higher than the share of incidence (49.3% and 5.7%, respectively) because of the different distribution of cancer types and higher case fatality rates in these regions.

Furthermore, increasing R&D research in the field of cancer immunotherapy is contributing to the emergence of innovative variants with improved treatment efficacy and effectiveness. Moreover, immuno-oncology has shown favorable results of increased survival and decreased toxicity. The overall demand is being propelled by a paradigm change away from conventional chemotherapies and toward immunotherapies.

Request Sample Copy of this Report @ https://univdatos.com/report/cancer-immunotherapy-market-current-analysis-and-forecast-2021-2027

COVID-19 Impact

The COVID-19 has resulted in a profound reevaluation of the advantages and costs of cancer care. Immunotherapy is becoming a key treatment option in conditions like melanoma, lung cancer, urothelial cancer, renal cancer, and head and neck cancer. During the current outbreak, there has been speculation of a correlation between immune-related adverse events and severe COVID-19. It was speculated that the physiological provocation from immunotherapy-mediated pneumonitis and SARSCoV2-related interstitial pneumonia corresponded. For instance, pneumonitis is the leading cause of hospitalization and death in COVID-19 patients. However, it is also observed to be an adverse event (AE) caused by immunotherapy (IMT), as it occurs in about 2% and 5% of patients undergoing IMT monotherapy and around 10% of patients receiving IMT combination therapy.

Ask for Price & Discounts @ https://univdatos.com/report/cancer-immunotherapy-market-current-analysis-and-forecast-2021-2027

Global Cancer Immunotherapy Market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

By Therapy, the market is primarily bifurcated into

  • Monoclonal Antibodies
  • Vaccines
  • Checkpoint Inhibitors
  • Cell Therapies
  • Immune System Modulators
  • Adoptive Cell Transfer
  • Cytokines
  • Others

Monoclonal antibodies segment dominated the by type of the global Cancer Immunotherapy market and will grow at 10.29% CAGR to reach US$ 65.13 billion by the year 2027.

By Application, the market is primarily segmented into

  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Melanoma
  • Prostate cancer
  • Head and neck cancer
  • Other Cancer Applications

Amongst application types, lung cancer accounted for the largest share in 2020 and is expected to grow at a 9.92% CAGR during the forecast period 2021-2027F. However, the breast cancer segment is anticipated to grow at the highest CAGR during the analyzed period and is expected to account for a revenue share of almost 20.71% by 2027.

Cancer Immunotherapy Market Geographical Segmentation Includes:

  • North America (United States, Canada)
  • Europe (Germany, United Kingdom, Italy, France, Spain, and Rest of Europe)
  • Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific)
  • Rest of the World

Based on the estimation, the North America region dominated the Cancer Immunotherapy market with almost US$ 37.56 billion revenue in 2020. At the same time, the Asia-Pacific region is expected to grow remarkably with a CAGR of 11.93% over the forecast period on account of the increasing population and cancer incidence.

Ask for Report Customization @ https://univdatos.com/report/cancer-immunotherapy-market-current-analysis-and-forecast-2021-2027

The major players targeting the market includes

  • AbbVie
  • Amgen
  • AstraZeneca
  • bluebird bio
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Janssen Biotech
  • Merck
  • Novartis
  • Pfizer

Competitive Landscape

The degree of competition among prominent global companies has been elaborated by analyzing several leading key players operating worldwide. The specialist team of research analysts sheds light on various traits such as global market competition, market share, most recent industry advancements, innovative product launches, partnerships, mergers, or acquisitions by leading companies in the Cancer Immunotherapy market. The major players have been analyzed by using research methodologies for getting insight views on global competition.

Key questions resolved through this analytical market research report include:

  • What are the latest trends, new patterns, and technological advancements in the Cancer Immunotherapy market?
  • Which factors are influencing the Cancer Immunotherapy market over the forecast period?
  • What are the global challenges, threats, and risks in the Cancer Immunotherapy market?
  • Which factors are propelling and restraining the Cancer Immunotherapy market?
  • What are the demanding global regions of the Cancer Immunotherapy market?
  • What will be the global market size in the upcoming years?
  • What are the crucial market acquisition strategies and policies applied by global companies?

We understand the requirement of different businesses, regions, and countries, we offer customized reports as per your requirements of business nature and geography. Please let us know If you have any custom needs.

For more informative information, please visit us @ https://univdatos.com/report/cancer-immunotherapy-market-current-analysis-and-forecast-2021-2027

About UnivDatos Market Insights

UnivDatos Market Insights (UMI) is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. Our research studies are spread across topics across the world, we cover markets in over 100 countries using smart research techniques and agile methodologies. We offer in-depth studies, detailed analysis, and customized reports that help shape winning business strategies for our clients.

Contact
UnivDatos Market Insights
Pawnendra Pawan
Client Development Lead
Ph: +91-7838604911
Email: pawnendra@univdatos.com
Website: https://univdatos.com/

Logo: https://mma.prnewswire.com/media/1225049/UnivDatos_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.